Published in Mol Cancer Ther on January 07, 2011
Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood (2011) 1.24
Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions. Chem Biol Drug Des (2013) 1.21
Targeting caspases in cancer therapeutics. Biol Chem (2013) 1.13
Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy. Int J Cell Biol (2013) 1.04
Dentatin Induces Apoptosis in Prostate Cancer Cells via Bcl-2, Bcl-xL, Survivin Downregulation, Caspase-9, -3/7 Activation, and NF-κB Inhibition. Evid Based Complement Alternat Med (2012) 1.04
Targeting survivin in cancer: novel drug development approaches. BioDrugs (2014) 0.98
AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther (2015) 0.96
Aurora B hyperactivation by Bub1 overexpression promotes chromosome missegregation. Cell Cycle (2011) 0.94
OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma. BMC Cancer (2013) 0.92
Cell death signaling and anticancer therapy. Front Oncol (2011) 0.91
Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide. Br J Clin Pharmacol (2011) 0.87
Manipulating the apoptotic pathway: potential therapeutics for cancer patients. Br J Clin Pharmacol (2013) 0.86
Survivin-targeting Artificial MicroRNAs Mediated by Adenovirus Suppress Tumor Activity in Cancer Cells and Xenograft Models. Mol Ther Nucleic Acids (2014) 0.85
Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma. Oncogene (2014) 0.84
The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. Oncotarget (2014) 0.84
Survivin promotion of melanoma metastasis requires upregulation of α5 integrin. Carcinogenesis (2013) 0.84
Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma. PLoS One (2013) 0.82
Effect of Terminal Groups of Dendrimers in the Complexation with Antisense Oligonucleotides and Cell Uptake. Nanoscale Res Lett (2016) 0.82
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs (2013) 0.81
Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis. Med Sci Monit (2015) 0.81
Theranostic properties of a survivin-directed molecular beacon in human melanoma cells. PLoS One (2014) 0.80
Correction of microtubule-kinetochore attachment errors: mechanisms and role in tumor suppression. Semin Cell Dev Biol (2011) 0.79
Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: potential role in therapy. Cancer Lett (2013) 0.79
Quantitative analysis of survivin protein expression and its therapeutic depletion by an antisense oligonucleotide in human lung tumors. Mol Ther Nucleic Acids (2012) 0.78
Potential molecular targeting of splice variants for cancer treatment. Indian J Exp Biol (2011) 0.78
Assessment of mRNA splice variants by qRT-PCR. Methods Mol Biol (2013) 0.76
Metastatic prostate cancer cell-specific phage-like particles as a targeted gene-delivery system. J Nanobiotechnology (2013) 0.76
Antisense Oligonucleotide Mediated Splice Correction of a Deep Intronic Mutation in OPA1. Mol Ther Nucleic Acids (2016) 0.75
BPIQ, a novel synthetic quinoline derivative, inhibits growth and induces mitochondrial apoptosis of lung cancer cells in vitro and in zebrafish xenograft model. BMC Cancer (2015) 0.75
Delivery of a survivin promoter-driven antisense survivin-expressing plasmid DNA as a cancer therapeutic: a proof-of-concept study. Onco Targets Ther (2016) 0.75
Sequestering survivin to functionalized nanoparticles: a strategy to enhance apoptosis in cancer cells. Biomater Sci (2016) 0.75
Anticancer Effects of Baicalein in Pancreatic Neuroendocrine Tumors In Vitro and In Vivo. Pancreas (2017) 0.75
Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT. Blood (2012) 1.63
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol (2004) 1.52
LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol (2003) 1.29
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs (2014) 1.26
Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia. Blood (2002) 1.18
Role of protein C in renal dysfunction after polymicrobial sepsis. J Am Soc Nephrol (2007) 1.18
Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol (2003) 1.02
One-step cellular caspase-3/7 assay. Biotechniques (2003) 1.00
Enhanced B cell expansion, survival, and humoral responses by targeting death receptor 6. J Exp Med (2003) 0.95
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol (2010) 0.93
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs (2014) 0.92
Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Prostate (2005) 0.89
High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides. J Biomol Screen (2007) 0.83
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors. Bioorg Med Chem Lett (2003) 0.83
TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis. Breast Cancer Res Treat (2015) 0.81
Resistance to myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis by death receptor 6-deficient mice. J Immunol (2005) 0.80
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines. Mol Cancer Ther (2004) 0.80
Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways. Oncogene (2002) 0.80
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles. Bioorg Med Chem Lett (2003) 0.79
Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiation. Stem Cells (2015) 0.79
Smad6s regulates plasminogen activator inhibitor-1 through a protein kinase C-beta-dependent up-regulation of transforming growth factor-beta. J Biol Chem (2005) 0.78
Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides. Bioorg Med Chem Lett (2003) 0.78
1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett (2004) 0.76
Biomarkers of the Hedgehog/Smoothened pathway in healthy volunteers. Am J Transl Res (2012) 0.75
A novel method for assessing in vitro oncology drug combinations using growth rates. J Biopharm Stat (2012) 0.75
Reversible gastric restriction implant: safety and efficacy in a canine model. Obes Surg (2011) 0.75
What is your diagnosis? Peripheral blood and venous thrombosis in a rhesus monkey. Vet Clin Pathol (1994) 0.75
Pleurotus ostreatus inhibits colitis-related colon carcinogenesis in mice. Int J Mol Med (2010) 0.75